An Immunophenotyping of Ovarian Cancer With Clinical and Immunological Significance
Immune checkpoint blockade (ICB), mainly anti-CTLA-4 and anti-PD-1/PD-L1 therapy, has showed promising clinical benefits in the treatment of some cancer types; however, its application in ovarian cancer is still in the primary stage. Immunophenotyping can help us understand the clinical characterist...
Main Authors: | Kai Yang, Weiwei Zhao, Ge Lou, Zhiwei Rong, Huan Xu, Wenjie Wang, Wei Song, Yuqing Cai, Yan Hou, Kang Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-04-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.00757/full |
Similar Items
-
Pattern of disease and response to pembrolizumab in recurrent cervical cancer
by: Kathryn M. Miller, et al.
Published: (2021-08-01) -
Immunoprofiling: An Encouraging Method for Predictive Factors Examination in Lung Cancer Patients Treated with Immunotherapy
by: Kamila Wojas-Krawczyk, et al.
Published: (2021-08-01) -
In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
by: Eric Bartee, et al.
Published: (2017-05-01) -
Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer
by: Emelie Rådestad, et al.
Published: (2019-02-01) -
Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy
by: Elena Shklovskaya, et al.
Published: (2020-09-01)